CAMBRIDGE, Mass. — Vizgen has announced two key appointments to strengthen its strategic and commercial growth.
Christian Uhrich, investment director at M Ventures—the corporate venture arm of Merck KGaA, Darmstadt, Germany—has joined Vizgen’s Board of Directors. His appointment follows M Ventures’ recent investment in Vizgen and aims to support the company’s long-term strategy. Uhrich brings extensive experience in life sciences investments, strategy, and operations.
Additionally, Chad Brown has been named Chief Commercial Officer (CCO). Brown, a veteran of the life sciences industry with more than 30 years of experience, has held leadership roles at NanoString, QIAGEN, and Roche Diagnostics. His expertise spans spatial biology, omics research, and clinical diagnostics.
“These additions to our board and leadership team reinforce our commitment to advancing spatial multi-omics and delivering value to our customers,” said Rob Carson, CEO of Vizgen. “Christian’s strategic insight and Chad’s commercial leadership come at a pivotal time as we enter a new product cycle.”
Brown expressed enthusiasm about his role, citing the recent merger of Vizgen and Ultivue as a transformative moment for spatial biology. “The new Vizgen is positioned to redefine spatial biology by integrating transcriptomics and proteomics into a comprehensive multi-omics solution,” he said.
Uhrich highlighted the field’s potential and M Ventures’ confidence in Vizgen’s future. “Spatial biology and multi-omics have vast applications from research to clinical use. Vizgen’s innovative platform and strong intellectual property portfolio make it a key player in this space,” he said.
M Ventures’ latest investment in Vizgen came as part of the company’s Series D financing in late 2024. The funding will support the commercialization of next-generation platforms, including the MERSCOPE Ultra™ instrument, and expansion of genomic and proteomic assay offerings.
